Mitsuo Terada
Overview
Explore the profile of Mitsuo Terada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Terada M, Miyashita M, Kumamaru H, Miyata H, Tamura K, Yoshida M, et al.
Breast Cancer
. 2022 Mar;
29(4):698-708.
PMID: 35316446
Background: Occult breast cancer (OBC) is classified as carcinoma of an unknown primary site, and the adequate therapy for OBC remains controversial. This retrospective study aimed to reveal the transition...
12.
Wanifuchi-Endo Y, Kondo N, Dong Y, Fujita T, Asano T, Hisada T, et al.
Oncol Lett
. 2022 Jan;
23(2):60.
PMID: 34992692
Taxanes are important drugs used in the treatment of breast cancer; however, some cancer types are taxane-resistant. The aim of the present study was to investigate the underlying mechanisms of...
13.
Mori M, Yoshimura A, Sawaki M, Hattori M, Kotani H, Adachi Y, et al.
Jpn J Clin Oncol
. 2021 Oct;
51(12):1703-1707.
PMID: 34599335
Background: Physicians recommend adjuvant therapy to patients based on baseline risk. A common recognition for baseline risk between patients and physicians is critical for successful adjuvant therapy. We prospectively investigated...
14.
Uemoto Y, Uchida M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, et al.
Breast Cancer
. 2021 Jul;
28(6):1346-1357.
PMID: 34292500
Background: Although chronic postsurgical pain (CPSP) after breast cancer surgery is a common and prevalent postsurgical adverse event, the need for CPSP treatment has not been investigated. This study examined...
15.
Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Kataoka A, et al.
BMC Cancer
. 2021 May;
21(1):548.
PMID: 33985457
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of paclitaxel (PTX). There is no known prophylactic measure, although there are some reports of prevention with compression therapy using...
16.
Nishikawa S, Uemoto Y, Kim T, Hisada T, Kondo N, Wanifuchi-Endo Y, et al.
Breast Cancer Res Treat
. 2021 Mar;
187(1):81-93.
PMID: 33782811
Purpose: Retinoic acid-induced 2 (RAI2) has been shown to be a putative suppressor of the early hematogenous dissemination of tumor cells to the bone marrow in breast cancer. Here, we...
17.
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, et al.
Breast Cancer
. 2021 Jan;
28(3):581-591.
PMID: 33389616
Background: Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are...
18.
Uemoto Y, Kondo N, Wanifuchi-Endo Y, Asano T, Hisada T, Nishikawa S, et al.
Jpn J Clin Oncol
. 2020 Aug;
50(12):1364-1369.
PMID: 32856072
Background: Current guidelines do not recommend that sentinel lymph node biopsy is routinely performed for ductal carcinoma in situ; thus, indications for sentinel lymph node biopsy in patients with ductal...
19.
Gondo N, Sawaki M, Hattori M, Yoshimura A, Kotani H, Adachi Y, et al.
Jpn J Clin Oncol
. 2020 Jan;
50(3):230-240.
PMID: 31958129
Objective: The relationship between the body mass index (BMI) at the time of breast cancer diagnosis and the prognosis of breast cancer patients has not yet been clarified. We investigated...
20.
Terada M, Yoshimura A, Sawaki M, Hattori M, Naomi G, Kotani H, et al.
Breast Cancer Res Treat
. 2019 Sep;
179(1):91-100.
PMID: 31535321
Purpose: Lymphedema (LE) decreases the quality of life of breast cancer patients. Objective quantification of PRO may improve the discordance between patient-reported outcomes (PROs) and objective assessments of LE by...